Peringatan Keamanan

In clinical studies, ?3% of patients experience abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nauseaFDA Label.

No information for treatment of overdose is available, however patients should be given milk or antacids to bind alendronic acid and vomiting should not be inducedFDA Label. Patients may experience hypocalcemia, hypophosphatemia, and upper gastrointestinal events.FDA Label.

There are currently no studies for safety and efficacy in pregnancy, though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal doseFDA Label.

Excretion in breast milk, and therefore safety in lactation, is unknownFDA Label.

Alendronic acid has been studied for use in pediatric patientsFDA Label. The oral bioavailability is similar to that in adult patients, but an increase in the portion of patients experiencing vomitingFDA Label.

There is no significant difference in efficacy or safety of alendronic acid in geriatric populations, though there is potential for even greater sensitivity in patients at a further advanced age than those in the studyFDA Label.

Alendronic acid is not recommended for patients with creatinine clearance <35mL/min, but no dosage adjustment is necessary in hepatic impairmentFDA Label.

Alendronic acid

DB00630

small molecule approved

Deskripsi

Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's diseaseFDA LabelA959,A203111. It functions by preventing resorption of boneFDA LabelA959.

Struktur Molekul 2D

Berat 249.096
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 years[FDA Label].
Volume Distribusi 28L[FDA Label].
Klirens (Clearance) 71mL/min[FDA Label].

Absorpsi

Mean oral bioavailability of alendronic acid in women is 0.64% and in men is 0.59%FDA LabelA176750. Bioavailability of alendronic acid decreases by up to 40% if it is taken within an hour of a mealFDA Label.

Metabolisme

Urinary excretion is the sole method of elimination of alendronic acid and no metabolites are detected upon urine collectionA176750.

Rute Eliminasi

Administration of radiolabeled alendronic acid results in 50% recovery in urine within 72 hoursFDA LabelA176771. No alendronic acid is recovered in the fecesFDA LabelA176750,A176768. Men excrete less alendronic acid than women, though race and advanced age do not affect eliminationFDA Label.

Interaksi Makanan

4 Data
  • 1. Administer vitamin supplements. Patients may require supplemental vitamin D.
  • 2. Avoid multivalent ions. Calcium, antacids, and divalent ions may interfere with the absorption of this medication.
  • 3. Take before a meal. Take 30-60 minutes before breakfast.
  • 4. Take with a full glass of water.

Interaksi Obat

416 Data
Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Alendronic acid is combined with Deferasirox.
Icosapent The risk or severity of adverse effects can be increased when Icosapent is combined with Alendronic acid.
Mesalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mesalazine is combined with Alendronic acid.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.
Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.
Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.
Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.
Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.
Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.
Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.
Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.
Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.
Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.
Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.
Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.
Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.
Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.
Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.
Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.
Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.
Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.
Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.
Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.
Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.
Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.
Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.
Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.
Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.
Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.
Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.
Olsalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Olsalazine is combined with Alendronic acid.
Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid.
Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alendronic acid.
Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.
Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid.
Antrafenine The risk or severity of adverse effects can be increased when Antrafenine is combined with Alendronic acid.
Aminophenazone The risk or severity of adverse effects can be increased when Aminophenazone is combined with Alendronic acid.
Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.
Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.
Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.
Taxifolin The risk or severity of adverse effects can be increased when Taxifolin is combined with Alendronic acid.
Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.
Licofelone The risk or severity of adverse effects can be increased when Licofelone is combined with Alendronic acid.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.
Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid.
Metamizole The risk or severity of nephrotoxicity and hypocalcemia can be increased when Metamizole is combined with Alendronic acid.
Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.
Cimicoxib The risk or severity of adverse effects can be increased when Cimicoxib is combined with Alendronic acid.
Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.
Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.
Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.
Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.
Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.
Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.
Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.
Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid.
Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid.
Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Alendronic acid.
Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.
Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.
Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.
Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid.
Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.
Dexibuprofen The risk or severity of adverse effects can be increased when Dexibuprofen is combined with Alendronic acid.
Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alendronic acid.
Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.
Tolfenamic acid The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Alendronic acid.
Firocoxib The risk or severity of adverse effects can be increased when Firocoxib is combined with Alendronic acid.
Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid.
Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Alendronic acid.
Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid.
Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Alendronic acid.
Robenacoxib The risk or severity of adverse effects can be increased when Robenacoxib is combined with Alendronic acid.
Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Alendronic acid.
Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Alendronic acid.
Polmacoxib The risk or severity of adverse effects can be increased when Polmacoxib is combined with Alendronic acid.
Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alendronic acid.
Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.
Ebselen The risk or severity of adverse effects can be increased when Ebselen is combined with Alendronic acid.
Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Alendronic acid.
Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid.
Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Alendronic acid.
Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Alendronic acid.
Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid.
Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.
Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Alendronic acid.
Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Alendronic acid.
Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid.
Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Alendronic acid.
Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid.
Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid.
Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Alendronic acid.
Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid.
Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alendronic acid.
Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid.
Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid.
Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid.
Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Alendronic acid.
Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.

Target Protein

Farnesyl pyrophosphate synthase FDPS
Hydroxylapatite
Tyrosine-protein phosphatase non-receptor type 4 PTPN4
Receptor-type tyrosine-protein phosphatase S PTPRS
Receptor-type tyrosine-protein phosphatase epsilon PTPRE
V-type proton ATPase catalytic subunit A ATP6V1A

Referensi & Sumber

Synthesis reference: Masahiko Dohi, Yuji Makino, Takao Hujii, "Sodium alendronate preparation for local administration." U.S. Patent US5958908, issued September, 1997.
Artikel (PubMed)
  • PMID: 18214569
    Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.
  • PMID: 10384857
    Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002.
  • PMID: 1356743
    Lin JH, Chen IW, Deluna FA, Hichens M: Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos. 1992 Jul-Aug;20(4):608-13.
  • PMID: 8246140
    Lin JH, Chen IW, deLuna FA, Hichens M: Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther. 1993 Nov;267(2):670-5.
  • PMID: 30650219
    Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28.

Contoh Produk & Brand

Produk: 269 • International brands: 20
Produk
  • Accel-alendronate
    Tablet • 5 mg • Oral • Canada • Generic • Approved
  • Accel-alendronate
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Accel-alendronate
    Tablet • 70 mg • Oral • Canada • Generic • Approved
  • Ach-alendronate
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Ach-alendronate
    Tablet • 70 mg • Oral • Canada • Generic • Approved
  • Ach-alendronate
    Tablet • 5 mg • Oral • Canada • Generic • Approved
  • Act Alendronate
    Tablet • 40 mg • Oral • Canada • Approved
  • Act Alendronate
    Tablet • 70 mg • Oral • Canada • Approved
Menampilkan 8 dari 269 produk.
International Brands
  • Alenotop — Pliva
  • Alned — Laboratorios Belmac
  • Arendal — Ivax
  • Beenos — Gedeon Richter
  • Berlex — Duncan
  • Denfos — Biofarma
  • Densidron — Mepha
  • Dronat — Farmavita
  • Durost — Perumed
  • Fixopan — Grupo Farma

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul